CyPath Lung Test Volume Surges 216% as bioAffinity Reports Q2 Results
BIAF is trading near its 52-week low of $0.513 (3.1% above the low).
Summary
bioAffinity's Q2 2026 results show CyPath Lung test volume up 216% year-over-year, with first-half revenue reaching $835K—a 159% increase. Physician adoption is accelerating: ordering offices grew 122%, and existing clients increased orders by 71%. The company also launched a longitudinal clinical trial at 11 VA and military sites, funded by the Murtha Cancer Center Research Program. This follows the $3.2M public offering closed in June, which addressed the urgent cash runway concern flagged in the Q1 filing. The strong commercial traction and trial initiation mark a pivotal shift from survival mode to execution. Next milestone: trial enrollment progress and Q3 sales data will indicate whether this growth trajectory is sustainable.
Updates
· SEC 8-K — Cash and cash equivalents were $2.4 million as of June 30, 2026, down from $6.4 million at December 31, 2025. Net loss for Q2 2026 was $3.4 million, compared with $4.1 million in Q2 2025.
At the time of this announcement, BIAF was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.51 to $13.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.